eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
3/2021
vol. 72
 
Share:
Send email
Share:
abstract:
Case report

Iris melanoma with ciliary body infiltration presenting as a presumed chronic unilateral inflammatory glaucoma. The challenges of iris tumor biopsy assessment

Agata Stodolska-Nowak
1
,
Wojciech Adamski
1
,
Agata Brązert
1
,
Jacek Sygut
2
,
Andrzej Marszałek
2
,
Iwona Rospond-Kubiak
1

1.
Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland
2.
Department of Cancer Pathology and Prophylaxis, Poznan University of Medical Sciences, The Greater Poland Cancer Centre, Poznan, Poland
Pol J Pathol 2021; 72 (3): 267-271
DOI: https://doi.org/10.5114/pjp.2021.111777
Online publish date: 2022/01/19
View full text Get citation
 
PlumX metrics:
Uveal melanoma is the most common primary malignancy of the eye in adults. It may involve the choroid and ciliary body, and in only 2-3% of cases it involves the iris.

We present a case of a 56-year-old patient with a 6-year history of unilateral, inflammatory, refractory glaucoma of the right eye. Due to acquired heterochromia and heterogeneous thickness of the iris, iris melanoma was suspected, but the incisional biopsy did not confirm the diagnosis. In the next months, the lesion enlarged and the eye globe was enucleated. Histopathological examination revealed an iridociliary melanoma with annular growth pattern.
keywords:

iris melanoma, ring melanoma, iris biopsy, unilateral glaucoma
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.